


## Valacyclovir-d<sub>8</sub> hydrochloride

<b>Cat. No.:</b>	HY-17425AS
<b>CAS No.:</b>	1279033-32-7
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>13</sub> D <sub>8</sub> ClN <sub>6</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	368.85
<b>Target:</b>	HSV; Antibiotic
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### BIOLOGICAL ACTIVITY

<b>Description</b>	Valacyclovir-d <sub>8</sub> (hydrochloride) is the deuterium labeled Valacyclovir hydrochloride. Valacyclovir hydrochloride (Valaciclovir hydrochloride) is an orally active antiviral agent for herpes simplex, herpes zoster, and herpes B. Valacyclovir hydrochloride inhibits HSV-1 W (50=2.9 µg/ml). Valacyclovir hydrochloride is a proagent of Aciclovir (HY-17422) [1][2][3][4][5].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Valacyclovir. New indication: for genital herpes, simpler administration. *Can Fam Physician.* 1999 Jul;45:1698-700, 1703-5.
- [3]. Lycke J, et al. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. *Antimicrob Agents Chemother.* 2003 Aug;47(8):2438-41.
- [4]. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. *Antimicrob Agents Chemother.* 1995 May;39(5):1114-9.
- [5]. Dhaliwal DK, Romanowski EG, Yates KA, Valacyclovir inhibits recovery of ocular HSV-1 after experimental reactivation by excimer laser keratectomy. *Cornea.* 1999 Nov;18(6):693-9.
- [6]. Guo A, Hu P, Balimane PV, Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. *J Pharmacol Exp Ther.* 1999 Apr;289(1):448-54.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA